Autolus Therapeutics (Autolus Therapeutics) Total Stockholders Equity : $582.03 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Autolus Therapeutics Total Stockholders Equity?

Autolus Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $582.03 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Autolus Therapeutics's Book Value per Share for the quarter that ended in Mar. 2024 was $2.19. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Autolus Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.09.

Autolus Therapeutics Total Stockholders Equity Historical Data

The historical data trend for Autolus Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Autolus Therapeutics Total Stockholders Equity Chart

Autolus Therapeutics Annual Data

Trend

Sep16

Sep17

Sep18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

254.84

210.03

313.32

298.67

111.47

Autolus Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial															266.92	229.34	180.52	111.47	582.03

Autolus Therapeutics (NAS:AUTL) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Autolus Therapeutics's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(582.03	-	0)	/	265.928
	=	2.19

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Autolus Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.818	+	46.518)	/	582.03
	=	0.09

Autolus Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Autolus Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Autolus Therapeutics (Autolus Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Autolus Therapeutics PLC (NAS:AUTL) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

6A3A:Germany

Address

191 Wood Lane, The MediaWorks, London, GBR, W12 7FP

Website

https://www.autolus.com

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.